From RTTNews:

Akoya Biosciences, Inc. (AKYA) anticipates fourth quarter revenue of $25.5 million to $26.5 million, up from last year’s $21.2 million. Fiscal 2023 revenue is expected to be $95.6 million to $96.6 million, compared to $74.9 million in 2022. Year end 2023 cash balance is projected to be $83.0 million to $85.0 million.

CEO Brian McKelligon expressed confidence in achieving cash flow positivity earlier than expected, with steady operating expenses and strong financial performance. The company expects 2024 revenue to grow over 20% and aims to achieve operating cash flow breakeven by year end 2024.

For more earnings news, visit rttnews.com. Contact [email protected] for comments and feedback. Visit rttnews.com for business news.



Read more: Akoya Biosciences Issues Preliminary Revenue Results; Issues 2024 Guidance